Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Geninus Inc. (389030:KRX), powered by AI.
Geninus Inc. is currently trading at ₩6,110. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Geninus Inc. on Alpha Lenz.
Geninus Inc.'s P/E ratio is -16.6.
“Geninus Inc. trades at a P/E of -16.6 (undervalued) with modest ROE of -43.3%.”
Ask for details →Geninus Inc. operates as a biotechnology firm focused on the development and commercialization of genomic insights and solutions. The company's primary function is to harness advanced genetic data to inform personalized medicine strategies and enhance patient outcomes. Geninus Inc. stands as a pivotal player in the healthcare and life sciences sector, facilitating precision medicine through its cutting-edge technology platforms and services. By offering diagnostic tools, sequencing solutions, and data analytics, Geninus Inc. empowers healthcare providers, researchers, and patients with actionable genomic information. The firm plays a critical role in the evolution of targeted therapies and personalized treatments, primarily impacting healthcare systems and pharmaceutical research. As genomic technology gains prominence, Geninus Inc.'s contributions are central to driving innovations in disease prediction, prevention, and treatment, highlighting its market significance and influence in shaping the future of medical and therapeutic landscapes.
“Geninus Inc. trades at a P/E of -16.6 (undervalued) with modest ROE of -43.3%.”
Ask for details →Geninus Inc. (ticker: 389030) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 74 employees. Market cap is $203.8B.
The current price is ₩6,110 with a P/E ratio of -16.59x and P/B of 9.16x.
ROE is -43.27% and operating margin is -189.91%. Annual revenue is $6.5B.